PMID- 36464889
OWN - NLM
STAT- MEDLINE
DCOM- 20230405
LR  - 20230409
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 6
DP  - 2023 Mar
TI  - Dendritic cell vaccines improve the glioma microenvironment: Influence, 
      challenges, and future directions.
PG  - 7207-7221
LID - 10.1002/cam4.5511 [doi]
AB  - INTRODUCTION: Gliomas, especially the glioblastomas, are one of the most 
      aggressive intracranial tumors with poor prognosis. This might be explained by 
      the heterogeneity of tumor cells and the inhibitory immunological 
      microenvironment. Dendritic cells (DCs), as the most potent in vivo functional 
      antigen-presenting cells, link innate immunity with adaptive immunity. However, 
      their function is suppressed in gliomas. Therefore, overcoming the dysfunction of 
      DCs in the TME might be critical to treat gliomas. METHOD: In this paper we 
      proposed the specificity of the glioma microenvironment, analyzed the pathways 
      leading to the dysfunction of DCs in tumor microenvironment of patients with 
      glioma, summarized influence of DC-based immunotherapy on the tumor 
      microenvironment and proposed new development directions and possible challenges 
      of DC vaccines. RESULT: DC vaccines can improve the immunosuppressive 
      microenvironment of glioma patients. It will bring good treatment prospects to 
      patients. We also proposed new development directions and possible challenges of 
      DC vaccines, thus providing an integrated understanding of efficacy on DC 
      vaccines for glioma treatment.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Zhou, Jing
AU  - Zhou J
AUID- ORCID: 0000-0002-0454-0528
AD  - NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated 
      Cancer Hospital of Xiangya School of Medicine, Central South University, 
      Changsha, Hunan, China.
AD  - Cancer Research Institute, Basic School of Medicine, Central South University, 
      Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the 
      Affiliated Cancer Hospital of Xiangya School of Medicine, Central South 
      University, Changsha, Hunan, China.
FAU - Li, Luohong
AU  - Li L
AD  - NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated 
      Cancer Hospital of Xiangya School of Medicine, Central South University, 
      Changsha, Hunan, China.
AD  - Cancer Research Institute, Basic School of Medicine, Central South University, 
      Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the 
      Affiliated Cancer Hospital of Xiangya School of Medicine, Central South 
      University, Changsha, Hunan, China.
FAU - Jia, Minqi
AU  - Jia M
AD  - Department of Radiation Oncology, Peking University Cancer Hospital & Institute, 
      Beijing, China.
FAU - Liao, Qianjin
AU  - Liao Q
AD  - Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the 
      Affiliated Cancer Hospital of Xiangya School of Medicine, Central South 
      University, Changsha, Hunan, China.
FAU - Peng, Guiping
AU  - Peng G
AD  - Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Luo, Gengqiu
AU  - Luo G
AD  - Department of Pathology, Xiangya Hospital, Basic School of Medicine, Central 
      South University, Changsha, Hunan, China.
FAU - Zhou, Yanhong
AU  - Zhou Y
AUID- ORCID: 0000-0002-9498-4439
AD  - NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated 
      Cancer Hospital of Xiangya School of Medicine, Central South University, 
      Changsha, Hunan, China.
AD  - Cancer Research Institute, Basic School of Medicine, Central South University, 
      Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the 
      Affiliated Cancer Hospital of Xiangya School of Medicine, Central South 
      University, Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221204
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Humans
MH  - Dendritic Cells
MH  - *Glioma/pathology
MH  - *Brain Neoplasms/therapy
MH  - Adaptive Immunity
MH  - Immunotherapy
MH  - *Cancer Vaccines/therapeutic use
MH  - Tumor Microenvironment
PMC - PMC10067114
OTO - NOTNLM
OT  - dendritic cells
OT  - glioma
OT  - treatment
OT  - tumor microenvironment
OT  - vaccine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2023/04/05 06:42
PMCR- 2022/12/04
CRDT- 2022/12/05 01:32
PHST- 2022/11/19 00:00 [revised]
PHST- 2022/07/21 00:00 [received]
PHST- 2022/11/24 00:00 [accepted]
PHST- 2023/04/05 06:42 [medline]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/05 01:32 [entrez]
PHST- 2022/12/04 00:00 [pmc-release]
AID - CAM45511 [pii]
AID - 10.1002/cam4.5511 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Mar;12(6):7207-7221. doi: 10.1002/cam4.5511. Epub 2022 Dec 4.